Duncan Williams Sees Large Takeover Potential in Obagi Medical Products (OMPI), Priced at 40%-60% Upside
OMPI Hot Sheet
Rating Summary:2 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 9 | New: 35
Duncan Williams is maintaining its Hold rating and $10 hypothetical price target on shares of Obagi Medical Products (NASDAQ: OMPI) as the company is still working through the Texas hydroquinone recall.
Management highlighted that roughly 10 percent of Texas accounts have abandoned the entire Obagi product line. The firm anticipates some contraction in the internet channel which represents around 10 percent of the company's total revenue.
Currently Obagi is a highly vulnerable target for a takeover since 50 percent of the stock is held by 6 shareholders, and 75 percent is held by 12 shareholders. Management noted that current takeover companies include large pharmaceutical companies, aesthetics companies, international players, and energy firms.
The firm forecasts that Obagi may be acquired for $270-$300 million (~40-60% upside), depending on the strategic value that Obagi offers the buyer.
An analyst at Duncan Williams comments, "We do think the brand is well recognized and the business could deliver solid cash flow growth into perpetuity if there were a way to replace hydroquinone with another effective, yet cosmetic ingredient that carries less FDA risk. We therefore think that a buyer for this company should emerge eventually, especially if management is unable to address the current challenges facing the company and there is additional pressure on the stock."
For more ratings news on Obagi Medical Products click here and for the rating history of Obagi Medical Products click here.
Shares of Obagi Medical Products closed at $9.82 yesterday, with a 52 week range of $8.61-$13.00.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Management highlighted that roughly 10 percent of Texas accounts have abandoned the entire Obagi product line. The firm anticipates some contraction in the internet channel which represents around 10 percent of the company's total revenue.
Currently Obagi is a highly vulnerable target for a takeover since 50 percent of the stock is held by 6 shareholders, and 75 percent is held by 12 shareholders. Management noted that current takeover companies include large pharmaceutical companies, aesthetics companies, international players, and energy firms.
The firm forecasts that Obagi may be acquired for $270-$300 million (~40-60% upside), depending on the strategic value that Obagi offers the buyer.
An analyst at Duncan Williams comments, "We do think the brand is well recognized and the business could deliver solid cash flow growth into perpetuity if there were a way to replace hydroquinone with another effective, yet cosmetic ingredient that carries less FDA risk. We therefore think that a buyer for this company should emerge eventually, especially if management is unable to address the current challenges facing the company and there is additional pressure on the stock."
For more ratings news on Obagi Medical Products click here and for the rating history of Obagi Medical Products click here.
Shares of Obagi Medical Products closed at $9.82 yesterday, with a 52 week range of $8.61-$13.00.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
- Canaccord Genuity Reiterates a 'Buy' on Analog Devices (ADI); Delivering Upside
- THE Aesthetic Academy Rolls Out the Red Carpet for Beverly Hills Celebrity Physicians at Exclusive Media Training Program June 2nd in Beverly Hills
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
